Related references
Note: Only part of the references are listed.All-Cause and Cause-Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Haseeb Chaudhary et al.
ARTHRITIS CARE & RESEARCH (2023)
Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis
Paolo Gisondi et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis
Maria Laura Acosta Felquer et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
Xenofon Baraliakos et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
Atul Deodhar et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
EFFICACY AND SAFETY OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AFTER INADEQUATE RESPONSE OR INTOLERANCE TO DMARDs: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 TRIAL
L. E. Kristensen et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Psoriatic arthritis
Oliver FitzGerald et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
Elsa Vieira-Sousa et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases
Lisa R. Sammaritano et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
Iain B. McInnes et al.
LANCET (2020)
Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
Elizabeth G. Araujo et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate
Leonieke J. J. van Mens et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
Jose U. Scher et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial
Philip J. Mease et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Bedside to bench: defining the immunopathogenesis of psoriatic arthritis
Arlene Bravo et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
Desiree van der Heijde et al.
LANCET (2019)
Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
Dafna D. Gladman et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
Desiree van der Heijde et al.
LANCET (2018)
Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study
Alvilde Maria Ossum et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Psoriasis and Psoriatic Arthritis-Related Uveitis: Different Ophthalmological Manifestations and Ocular Inflammation Features
Alessandro Abbouda et al.
SEMINARS IN OPHTHALMOLOGY (2017)
A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis
William Tillett et al.
JOURNAL OF RHEUMATOLOGY (2017)
Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group
Alexis Ogdie et al.
JOURNAL OF RHEUMATOLOGY (2017)
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study
Laura C. Coates et al.
JOURNAL OF RHEUMATOLOGY (2016)
Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
Arthur Kavanaugh et al.
JOURNAL OF RHEUMATOLOGY (2016)
Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort
Margarita Landi et al.
MEDICINE (2016)
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial
Laura C. Coates et al.
LANCET (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical features and types of articular involvement in patients with psoriatic arthritis
Salim Donmez et al.
CLINICAL RHEUMATOLOGY (2015)
Epidemiology and Potential Pathomechanisms of Cardiovascular Comorbidities in Psoriasis: A Report from the GRAPPA 2010 Annual Meeting
W.-H. BOEHNCKE
JOURNAL OF RHEUMATOLOGY (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Treatment recommendations for psoriatic arthritis
C. T. Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Share Paper
